JP2015502365A5 - - Google Patents

Download PDF

Info

Publication number: JP2015502365A5
Authority: JP; Japan
Prior art keywords: diseases; disorders; oligonucleotide; composition; disease
Prior art date: 2012-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2014547389A

Other languages

English (en)

Japanese (ja)

Other versions

JP2015502365A (ja

Filing date

2012-12-12

Publication date

2017-06-15

2012-12-12 Application filed filed Critical

2012-12-12 Priority claimed from PCT/US2012/069294 external-priority patent/WO2013090457A2/en

2015-01-22 Publication of JP2015502365A publication Critical patent/JP2015502365A/ja

2017-06-15 Publication of JP2015502365A5 publication Critical patent/JP2015502365A5/ja

Status Pending legal-status Critical Current

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
108091034117 Oligonucleotide Proteins 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 13
208000035475 disorder Diseases 0.000 claims description 13
230000001225 therapeutic effect Effects 0.000 claims description 13
239000000074 antisense oligonucleotide Substances 0.000 claims description 4
238000012230 antisense oligonucleotides Methods 0.000 claims description 4
230000014509 gene expression Effects 0.000 claims description 3
230000009368 gene silencing by RNA Effects 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 2
238000012986 modification Methods 0.000 claims description 2
230000004048 modification Effects 0.000 claims description 2
150000007523 nucleic acids Chemical group 0.000 claims 10
108020004707 nucleic acids Proteins 0.000 claims 9
102000039446 nucleic acids Human genes 0.000 claims 9
239000002679 microRNA Substances 0.000 claims 7
239000002773 nucleotide Substances 0.000 claims 7
125000003729 nucleotide group Chemical group 0.000 claims 7
102000004169 proteins and genes Human genes 0.000 claims 7
108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
239000000758 substrate Substances 0.000 claims 5
208000024172 Cardiovascular disease Diseases 0.000 claims 4
208000012902 Nervous system disease Diseases 0.000 claims 4
208000025966 Neurological disease Diseases 0.000 claims 4
108091005461 Nucleic proteins Proteins 0.000 claims 4
230000002159 abnormal effect Effects 0.000 claims 4
208000026278 immune system disease Diseases 0.000 claims 4
208000027866 inflammatory disease Diseases 0.000 claims 4
108020004999 messenger RNA Proteins 0.000 claims 4
208000030159 metabolic disease Diseases 0.000 claims 4
230000002018 overexpression Effects 0.000 claims 4
230000009452 underexpressoin Effects 0.000 claims 4
101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims 3
108091070501 miRNA Proteins 0.000 claims 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
108090000623 proteins and genes Proteins 0.000 claims 3
208000035473 Communicable disease Diseases 0.000 claims 2
108020004414 DNA Proteins 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 claims 2
238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
108091027967 Small hairpin RNA Proteins 0.000 claims 2
108020004459 Small interfering RNA Proteins 0.000 claims 2
201000011510 cancer Diseases 0.000 claims 2
208000030533 eye disease Diseases 0.000 claims 2
230000002062 proliferating effect Effects 0.000 claims 2
208000017520 skin disease Diseases 0.000 claims 2
239000004055 small Interfering RNA Substances 0.000 claims 2
108091023037 Aptamer Proteins 0.000 claims 1
108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
108091028043 Nucleic acid sequence Proteins 0.000 claims 1
108091081024 Start codon Proteins 0.000 claims 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
108091036066 Three prime untranslated region Proteins 0.000 claims 1
230000000692 anti-sense effect Effects 0.000 claims 1
230000033228 biological regulation Effects 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
230000000295 complement effect Effects 0.000 claims 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
238000000034 method Methods 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
230000003278 mimic effect Effects 0.000 claims 1
239000002777 nucleoside Substances 0.000 claims 1
150000003833 nucleoside derivatives Chemical class 0.000 claims 1
125000003835 nucleoside group Chemical class 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 claims 1
150000008039 phosphoramides Chemical class 0.000 claims 1
108091007428 primary miRNA Proteins 0.000 claims 1
239000002924 silencing RNA Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000003093 intracellular space Anatomy 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1

JP2014547389A 2011-12-12 2012-12-12 オリゴヌクレオチドのイン−ビボ送達 Pending JP2015502365A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161630446P	2011-12-12	2011-12-12
US61/630,446		2011-12-12
PCT/US2012/069294 WO2013090457A2 (en)	2011-12-12	2012-12-12	In vivo delivery of oligonucleotides

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019017110A Division JP2019073548A (ja)	2011-12-12	2019-02-01	オリゴヌクレオチドのイン−ビボ送達

Publications (2)

Publication Number	Publication Date
JP2015502365A JP2015502365A (ja)	2015-01-22
JP2015502365A5 true JP2015502365A5 (2)	2017-06-15

Family

ID=48613358

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2014547389A Pending JP2015502365A (ja)	2011-12-12	2012-12-12	オリゴヌクレオチドのイン−ビボ送達
JP2019017110A Pending JP2019073548A (ja)	2011-12-12	2019-02-01	オリゴヌクレオチドのイン−ビボ送達

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2019017110A Pending JP2019073548A (ja)	2011-12-12	2019-02-01	オリゴヌクレオチドのイン−ビボ送達

Country Status (6)

Country	Link
US (4)	US10557136B2 (2)
EP (1)	EP2790736B1 (2)
JP (2)	JP2015502365A (2)
CA (1)	CA2895077A1 (2)
DK (1)	DK2790736T3 (2)
WO (1)	WO2013090457A2 (2)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2639852T3 (es)	2007-10-26	2017-10-30	Academisch Ziekenhuis Leiden	Medios y métodos para contrarrestar los trastornos musculares
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
KR20140004646A (ko)	2010-12-15	2014-01-13	미라젠 세러퓨틱스	잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
KR20140091688A (ko)	2011-10-06	2014-07-22	미라젠 세러퓨틱스 인코포레이티드	마이크로rna 조절에 의한 전신 에너지 항상성의 제어
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
CN107236735B (zh)	2012-06-21	2019-11-08	米拉根医疗股份有限公司	包含锁核酸基序的基于寡核苷酸的抑制剂
EP2870246B1 (en) *	2012-07-03	2019-09-11	BioMarin Technologies B.V.	Oligonucleotide for the treatment of muscular dystrophy patients
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
WO2014159990A1 (en)	2013-03-13	2014-10-02	Yale University	Interferon production using short rna duplexes
EP3007705A4 (en) *	2013-06-12	2017-02-15	Oncoimmunin, Inc.	Systemic in vivo delivery of oligonucleotides
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2015161255A1 (en) *	2014-04-18	2015-10-22	Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno	Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
MA39990A (fr) *	2014-05-16	2015-11-19	Univ Pennsylvania	Induction de régénération cardiaque par micro-arn
EP3247716A4 (en)	2015-01-20	2018-10-17	Miragen Therapeutics, Inc.	Mir-92 inhibitors and uses thereof
IL295755A (en) *	2015-10-09	2022-10-01	Wave Life Sciences Ltd	Oligonucleotide compositions and methods thereof
US11466270B2 (en) *	2016-10-04	2022-10-11	Vib Vzw	Means and methods to treat inflammatory diseases
EP3810151B1 (en)	2018-06-20	2025-08-06	Yale University	Rig-i agonists and treatments using same
US20200318113A1 (en) *	2019-03-05	2020-10-08	MiRagen Therapeutics, Inc.	Polynucleotide conjugates and uses thereof
EP3947680A2 (en) *	2019-04-03	2022-02-09	Bristol-Myers Squibb Company	Angptl2 antisense oligonucleotides and uses thereof
JP7692829B2 (ja) *	2019-07-30	2025-06-16	塩野義製薬株式会社	Ｍｕｒｆ１を標的とする核酸医薬
CA3167444A1 (en) *	2020-01-11	2021-07-15	Oncoimmunin, Inc.	Targeted and localized in vivo delivery of oligonucleotides
US11786545B2 (en)	2020-12-09	2023-10-17	Yale University	Compositions and methods for treating SARS-CoV-2 infection
US11649457B2 (en)	2020-12-09	2023-05-16	Yale University	Methods for treating SARS-CoV-2 infection
WO2022232223A1 (en) *	2021-04-28	2022-11-03	The Johns Hopkins University	Treating cancer
US20230065782A1 (en) *	2021-07-14	2023-03-02	Oncoimmunin, Inc.	Targeted and localized in vivo delivery of oligonucleotides
CN113975397B (zh) *	2021-10-26	2023-08-22	中南大学湘雅三医院	一种基因/小分子化合物纳米递药系统及其制备方法与应用

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4476301A (en)	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja)	1982-08-09	1984-02-14	Wakunaga Seiyaku Kk	固定化オリゴヌクレオチド
FR2540122B1 (fr)	1983-01-27	1985-11-29	Centre Nat Rech Scient	Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en)	1983-02-14	1986-08-12	Wakunaga Seiyaku Kabushiki Kaisha	Oligonucleotide derivatives
US4948882A (en)	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en)	1983-03-10	1989-04-25	Julian Gordon	Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
USRE34069E (en)	1983-08-18	1992-09-15	Biosyntech Gmbh	Process for the preparation of oligonucleotides
DE3329892A1 (de)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
US4587044A (en)	1983-09-01	1986-05-06	The Johns Hopkins University	Linkage of proteins to nucleic acids
US5118802A (en)	1983-12-20	1992-06-02	California Institute Of Technology	DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en)	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5258506A (en)	1984-10-16	1993-11-02	Chiron Corporation	Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en)	1984-10-16	1995-07-04	Chiron Corporation	Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
US4828979A (en)	1984-11-08	1989-05-09	Life Technologies, Inc.	Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (fr)	1985-01-08	1987-04-03	Pasteur Institut	Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en)	1989-12-20	1995-04-11	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US4762779A (en)	1985-06-13	1988-08-09	Amgen Inc.	Compositions and methods for functionalizing nucleic acids
US5317098A (en)	1986-03-17	1994-05-31	Hiroaki Shizuya	Non-radioisotope tagging of fragments
JPS638396A (ja)	1986-06-30	1988-01-14	Wakunaga Pharmaceut Co Ltd	ポリ標識化オリゴヌクレオチド誘導体
EP0260032B1 (en)	1986-09-08	1994-01-26	Ajinomoto Co., Inc.	Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en)	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
EP0366685B1 (en)	1987-06-24	1994-10-19	Howard Florey Institute Of Experimental Physiology And Medicine	Nucleoside derivatives
US5585481A (en)	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US5188897A (en)	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en)	1987-10-28	1996-06-11	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de)	1987-11-12	1989-05-24	Max Planck Gesellschaft	Modifizierte oligonukleotide
ATE151467T1 (de)	1987-11-30	1997-04-15	Univ Iowa Res Found	Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5403711A (en)	1987-11-30	1995-04-04	University Of Iowa Research Foundation	Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5082830A (en)	1988-02-26	1992-01-21	Enzo Biochem, Inc.	End labeled nucleotide probe
JPH03503894A (ja)	1988-03-25	1991-08-29	ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション	オリゴヌクレオチド　ｎ‐アルキルホスホラミデート
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5262536A (en)	1988-09-15	1993-11-16	E. I. Du Pont De Nemours And Company	Reagents for the preparation of 5'-tagged oligonucleotides
US5194599A (en)	1988-09-23	1993-03-16	Gilead Sciences, Inc.	Hydrogen phosphonodithioate compositions
US5512439A (en)	1988-11-21	1996-04-30	Dynal As	Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en)	1989-03-06	1997-02-04	Board Of Regents, University Of Tx	Texaphyrin metal complexes having improved functionalization
US5457183A (en)	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US5391723A (en)	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5451463A (en)	1989-08-28	1995-09-19	Clontech Laboratories, Inc.	Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
AU637800B2 (en)	1989-08-31	1993-06-10	City Of Hope	Chimeric dna-rna catalytic sequences
US5254469A (en)	1989-09-12	1993-10-19	Eastman Kodak Company	Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5721218A (en)	1989-10-23	1998-02-24	Gilead Sciences, Inc.	Oligonucleotides with inverted polarity
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5264562A (en)	1989-10-24	1993-11-23	Gilead Sciences, Inc.	Oligonucleotide analogs with novel linkages
DE69034150T2 (de)	1989-10-24	2005-08-25	Isis Pharmaceuticals, Inc., Carlsbad	2'-Modifizierte Oligonukleotide
US5292873A (en)	1989-11-29	1994-03-08	The Research Foundation Of State University Of New York	Nucleic acids labeled with naphthoquinone probe
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en)	1990-01-08	1996-01-23	Gilead Sciences, Inc.	Oligonucleotide having enhanced binding affinity
US6114513A (en)	1990-01-11	2000-09-05	Isis Pharmaceuticals, Inc.	Thiol-derivatized oligonucleotides
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5623065A (en)	1990-08-13	1997-04-22	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US5578718A (en)	1990-01-11	1996-11-26	Isis Pharmaceuticals, Inc.	Thiol-derivatized nucleosides
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en)	1990-02-15	1993-06-15	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of RNA and production of encoded polypeptides
AU7579991A (en)	1990-02-20	1991-09-18	Gilead Sciences, Inc.	Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en)	1990-02-20	1993-05-25	Gilead Sciences, Inc.	Anthraquinone-derivatives oligonucleotides
US5321131A (en)	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es)	1990-05-11	1998-08-01	Microprobe Corp	Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US6365730B1 (en)	1990-06-19	2002-04-02	Gene Shears Pty. Limited	DNA-Armed ribozymes and minizymes
JPH0874B2 (ja)	1990-07-27	1996-01-10	アイシス・ファーマシューティカルス・インコーポレーテッド	遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5688941A (en)	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5386023A (en)	1990-07-27	1995-01-31	Isis Pharmaceuticals	Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5218105A (en)	1990-07-27	1993-06-08	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5245022A (en)	1990-08-03	1993-09-14	Sterling Drug, Inc.	Exonuclease resistant terminally substituted oligonucleotides
MY107332A (en)	1990-08-03	1995-11-30	Sterling Drug Inc	Compounds and methods for inhibiting gene expression.
US5177196A (en)	1990-08-16	1993-01-05	Microprobe Corporation	Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en)	1990-08-28	1996-04-30	Reed; Michael W.	Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en)	1990-09-12	1993-05-25	Sterling Winthrop Inc.	Process of linking nucleosides with a siloxane bridge
US5561225A (en)	1990-09-19	1996-10-01	Southern Research Institute	Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja)	1990-09-20	1994-06-30	ギリアド　サイエンシズ，インコーポレイテッド	改変ヌクレオシド間結合
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
ES2061416T3 (es)	1990-10-12	1997-03-01	Max Planck Gesellschaft	Ribozimas modificadas.
KR930702373A (ko)	1990-11-08	1993-09-08	안토니 제이. 페이네	합성 올리고누클레오티드에 대한 다중 리포터(Reporter)그룹의 첨합
US5672697A (en)	1991-02-08	1997-09-30	Gilead Sciences, Inc.	Nucleoside 5'-methylene phosphonates
US5719262A (en)	1993-11-22	1998-02-17	Buchardt, Deceased; Ole	Peptide nucleic acids having amino acid side chains
US5539082A (en)	1993-04-26	1996-07-23	Nielsen; Peter E.	Peptide nucleic acids
US5714331A (en)	1991-05-24	1998-02-03	Buchardt, Deceased; Ole	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DE4216134A1 (de)	1991-06-20	1992-12-24	Europ Lab Molekularbiolog	Synthetische katalytische oligonukleotidstrukturen
DK0593618T3 (da)	1991-06-27	1998-11-23	Genelabs Tech Inc	Screeningsassay til påvisning af DNA-bindende molekyler
US5371241A (en)	1991-07-19	1994-12-06	Pharmacia P-L Biochemicals Inc.	Fluorescein labelled phosphoramidites
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (de)	1991-10-17	1997-06-04	Novartis AG	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE69233046T2 (de)	1991-10-24	2004-03-04	Isis Pharmaceuticals, Inc., Carlsfeld	Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en)	1991-11-26	2000-06-11	Isis Pharmaceuticals Inc	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en)	1991-11-26	1993-06-28	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en)	1991-12-12	1998-08-11	Gilead Sciences, Inc.	Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
US5700922A (en)	1991-12-24	1997-12-23	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
US5644048A (en)	1992-01-10	1997-07-01	Isis Pharmaceuticals, Inc.	Process for preparing phosphorothioate oligonucleotides
US5595726A (en)	1992-01-21	1997-01-21	Pharmacyclics, Inc.	Chromophore probe for detection of nucleic acid
US5565552A (en)	1992-01-21	1996-10-15	Pharmacyclics, Inc.	Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5652094A (en)	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
US5633360A (en)	1992-04-14	1997-05-27	Gilead Sciences, Inc.	Oligonucleotide analogs capable of passive cell membrane permeation
EP0642589A4 (en)	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5434257A (en)	1992-06-01	1995-07-18	Gilead Sciences, Inc.	Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
PL172710B1 (pl)	1992-07-02	1997-11-28	Hybridon Inc	Samostabilizujacy sie oligonukleotyd PL PL
US5272250A (en)	1992-07-10	1993-12-21	Spielvogel Bernard F	Boronated phosphoramidate compounds
EP0786522A2 (en)	1992-07-17	1997-07-30	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecules for treatment of stenotic conditions
US5652355A (en)	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
CA2159631A1 (en)	1993-03-30	1994-10-13	Sanofi	Acyclic nucleoside analogs and oligonucleotide sequences containing them
HU9501974D0 (en)	1993-03-31	1995-09-28	Sterling Winthrop Inc	Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
DE733059T1 (de)	1993-12-09	1997-08-28	Univ Jefferson	Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5637684A (en)	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en)	1994-04-28	1997-07-08	Gilead Sciences, Inc.	Method for oligonucleotide analog synthesis
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
US5597696A (en)	1994-07-18	1997-01-28	Becton Dickinson And Company	Covalent cyanine dye oligonucleotide conjugates
US5580731A (en)	1994-08-25	1996-12-03	Chiron Corporation	N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5652356A (en)	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
WO1997026270A2 (en)	1996-01-16	1997-07-24	Ribozyme Pharmaceuticals, Inc.	Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US6893868B2 (en) *	1997-02-20	2005-05-17	Onco Immunin, Inc.	Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
WO2001018238A1 (en) *	1999-09-10	2001-03-15	Oncoimmunin, Inc.	Compositions for the detection of enzyme activity in biological samples and methods of use thereof
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
JP4236812B2 (ja)	1997-09-12	2009-03-11	エクシコンエ／エス	オリゴヌクレオチド類似体
US6007992A (en)	1997-11-10	1999-12-28	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6028183A (en)	1997-11-07	2000-02-22	Gilead Sciences, Inc.	Pyrimidine derivatives and oligonucleotides containing same
AU4102099A (en)	1998-05-29	1999-12-13	Heska Corporation	Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
ES2234563T5 (es)	1999-02-12	2018-01-17	Daiichi Sankyo Company, Limited	Nuevos análogos de nucleósidos y oligonucleótidos
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
JP4151751B2 (ja)	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6287860B1 (en)	2000-01-20	2001-09-11	Isis Pharmaceuticals, Inc.	Antisense inhibition of MEKK2 expression
US20030158403A1 (en)	2001-07-03	2003-08-21	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
CA2452458A1 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
CA2459347C (en)	2001-09-04	2012-10-09	Exiqon A/S	Locked nucleic acid (lna) compositions and uses thereof
GB2406169B (en) *	2002-06-12	2006-11-01	Ambion Inc	Methods and compositions relating to labeled rna molecules that reduce gene expression
US20060228800A1 (en)	2003-05-15	2006-10-12	Shi-Lung Lin	Novel Transgenic Methods Using intronic RNA
US20090203141A1 (en)	2003-05-15	2009-08-13	Shi-Lung Lin	Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents
US9567591B2 (en)	2003-05-15	2017-02-14	Mello Biotechnology, Inc.	Generation of human embryonic stem-like cells using intronic RNA
US20050142581A1 (en) *	2003-09-04	2005-06-30	Griffey Richard H.	Microrna as ligands and target molecules
CA2538252C (en)	2003-09-18	2014-02-25	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
US20120122104A1 (en)	2006-03-26	2012-05-17	Applera Corporation	Triple-Stranded Nucleobase Structures and Uses Thereof
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
WO2008147430A2 (en)	2006-10-11	2008-12-04	Nucleonics, Inc.	Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
WO2008101157A1 (en)	2007-02-15	2008-08-21	Isis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
US20100280098A1 (en) *	2007-10-05	2010-11-04	Juliano Rudolph L	Receptor targeted oligonucleotides
JP5558097B2 (ja)	2007-12-10	2014-07-23	国立大学法人京都大学	効率的な核初期化方法
US9683232B2 (en)	2007-12-10	2017-06-20	Kyoto University	Efficient method for nuclear reprogramming
US7977321B2 (en) *	2008-02-12	2011-07-12	University Of Tennessee Research Foundation	Small interfering RNAs targeting feline herpes virus
CN111808084A (zh)	2008-11-10	2020-10-23	阿布特斯生物制药公司	用于递送治疗剂的新型脂质和组合物
EP3243504A1 (en)	2009-01-29	2017-11-15	Arbutus Biopharma Corporation	Improved lipid formulation
SG10201911942UA (en)	2009-05-05	2020-02-27	Muthiah Manoharan	Lipid compositions
AU2010324658A1 (en) *	2009-11-26	2012-05-03	Quark Pharmaceuticals, Inc.	siRNA compounds comprising terminal substitutions
WO2011072082A2 (en) *	2009-12-09	2011-06-16	Nitto Denko Corporation	Modulation of hsp47 expression
JP2015502365A (ja) *	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達

2012
- 2012-12-12 JP JP2014547389A patent/JP2015502365A/ja active Pending
- 2012-12-12 CA CA2895077A patent/CA2895077A1/en not_active Abandoned
- 2012-12-12 US US14/648,369 patent/US10557136B2/en active Active
- 2012-12-12 DK DK12858522.1T patent/DK2790736T3/en active
- 2012-12-12 EP EP12858522.1A patent/EP2790736B1/en active Active
- 2012-12-12 WO PCT/US2012/069294 patent/WO2013090457A2/en not_active Ceased
2019
- 2019-02-01 JP JP2019017110A patent/JP2019073548A/ja active Pending
- 2019-12-18 US US16/718,911 patent/US11261443B2/en active Active
2022
- 2022-01-26 US US17/584,854 patent/US20220170017A1/en not_active Abandoned
2024
- 2024-01-24 US US18/421,570 patent/US20240401040A1/en active Pending

Publication	Publication Date	Title
JP2015502365A5 (2)	2017-06-15
CN115666659B (zh)	2026-03-03	稳定性增加的修饰的寡核苷酸的合成
JP2016521753A5 (2)	2021-07-29
JP2025072451A (ja)	2025-05-09	安定性が増加した修飾オリゴヌクレオチド
Lennox et al.	2011	Chemical modification and design of anti-miRNA oligonucleotides
EP3099797B1 (en)	2019-08-21	Poly oligomer compound with biocleavable conjugates
US10538763B2 (en)	2020-01-21	Compounds and methods for modulation of DUX4
ES2739804T3 (es)	2020-02-04	Compuestos terapéuticos
DK2790736T3 (en)	2018-05-07	In vivo delivery of oligonucleotides
JP2025156319A (ja)	2025-10-14	組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
McDermott et al.	2011	The therapeutic potential of microRNAs: disease modulators and drug targets
Pan et al.	2010	MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases
JP2014527401A5 (2)	2015-08-06
CA3133784A1 (en)	2020-10-08	Oligonucleotide-based modulation of c9orf72
JP2013510561A5 (2)	2014-01-09
Frost et al.	2010	miRNAs as therapeutic targets in ischemic heart disease
JP2016513976A5 (2)	2017-04-20
CA2921457A1 (en)	2015-02-19	Heterochromatin forming non-coding rnas
CA2951816A1 (en)	2014-12-18	Systemic in vivo delivery of oligonucleotides
Ruberti et al.	2012	Targeting microRNAs in neurons: tools and perspectives
JP2016520310A5 (2)	2017-06-01
JP2017511694A (ja)	2017-04-27	マイクロｒｎａ阻害剤を使用するための組成物および方法
US20220154185A1 (en)	2022-05-19	HETERO DOUBLE-STRANDED antimiR
AU2022299514A1 (en)	2024-01-18	Products and compositions
JP6934695B2 (ja)	2021-09-15	核酸医薬とその使用